A class-action complaint in the Northern District of Illinois alleges Tempus AI compelled Ambry Genetics to disclose customer genetic data without consent after acquiring Ambry in a $600 million deal. Plaintiff Jennifer Nash claims disclosures violated Illinois’ Genetic Information Privacy Act, and accuses Tempus of sharing de-identified data with numerous pharma partners — including AstraZeneca, Pfizer, Novartis and Merck — in ways the suit alleges were neither authorized nor truly anonymized. The filing cites Ambry’s 2020 breach affecting over 200,000 customers to argue re-identification risk. Tempus and Ambry have maintained they share only de-identified data; the suit challenges those assurances and could prompt scrutiny of data licensing practices across genomic platform deals.